163 related articles for article (PubMed ID: 35728726)
1. Irinotecan decreases intestinal UDP-glucuronosyltransferase (UGT) 1A1 via TLR4/MyD88 pathway prior to the onset of diarrhea.
Tao G; Dagher F; Li L; Singh R; Hu M; Ghose R
Food Chem Toxicol; 2022 Aug; 166():113246. PubMed ID: 35728726
[TBL] [Abstract][Full Text] [Related]
2. The contribution of intestinal UDP-glucuronosyltransferases in modulating 7-ethyl-10-hydroxy-camptothecin (SN-38)-induced gastrointestinal toxicity in rats.
Tallman MN; Miles KK; Kessler FK; Nielsen JN; Tian X; Ritter JK; Smith PC
J Pharmacol Exp Ther; 2007 Jan; 320(1):29-37. PubMed ID: 17003228
[TBL] [Abstract][Full Text] [Related]
3. The Adaptor Protein Myd88 Is a Key Signaling Molecule in the Pathogenesis of Irinotecan-Induced Intestinal Mucositis.
Wong DV; Lima-Júnior RC; Carvalho CB; Borges VF; Wanderley CW; Bem AX; Leite CA; Teixeira MA; Batista GL; Silva RL; Cunha TM; Brito GA; Almeida PR; Cunha FQ; Ribeiro RA
PLoS One; 2015; 10(10):e0139985. PubMed ID: 26440613
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan-mediated diarrhea is mainly correlated with intestinal exposure to SN-38: Critical role of gut Ugt.
Sun R; Zhu L; Li L; Song W; Gong X; Qi X; Wang Y; Ghose R; Gao S; Hu M; Liu Z
Toxicol Appl Pharmacol; 2020 Jul; 398():115032. PubMed ID: 32387182
[TBL] [Abstract][Full Text] [Related]
5. Role of Toll-like receptor 4 in drug-drug interaction between paclitaxel and irinotecan in vitro.
Mallick P; Basu S; Moorthy B; Ghose R
Toxicol In Vitro; 2017 Jun; 41():75-82. PubMed ID: 28242239
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.
Ando Y; Ueoka H; Sugiyama T; Ichiki M; Shimokata K; Hasegawa Y
Ther Drug Monit; 2002 Feb; 24(1):111-6. PubMed ID: 11805731
[TBL] [Abstract][Full Text] [Related]
7. Intestinal UDP-Glucuronosyltransferase 1A1 and Protection against Irinotecan-Induced Toxicity in a Novel UDP-Glucuronosyltransferase 1A1 Tissue-Specific Humanized Mouse Model.
Mennillo E; Yang X; Weber AA; Maruo Y; Verreault M; Barbier O; Chen S; Tukey RH
Drug Metab Dispos; 2022 Jan; 50(1):33-42. PubMed ID: 34697081
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
[TBL] [Abstract][Full Text] [Related]
9. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
[TBL] [Abstract][Full Text] [Related]
10. Development of a physiologically based pharmacokinetic model to predict irinotecan disposition during inflammation.
Tao G; Chityala PK; Li L; Lin Z; Ghose R
Chem Biol Interact; 2022 Jun; 360():109946. PubMed ID: 35430260
[TBL] [Abstract][Full Text] [Related]
11. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
Kurita A; Kado S; Matsumoto T; Asakawa N; Kaneda N; Kato I; Uchida K; Onoue M; Yokokura T
Cancer Chemother Pharmacol; 2011 Jan; 67(1):201-13. PubMed ID: 20354702
[TBL] [Abstract][Full Text] [Related]
12. Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation.
Tagawa K; Maruo Y; Mimura Y; Ikushiro S
Toxicol Mech Methods; 2023 Mar; 33(3):197-205. PubMed ID: 35930428
[TBL] [Abstract][Full Text] [Related]
13. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
Iyer L; King CD; Whitington PF; Green MD; Roy SK; Tephly TR; Coffman BL; Ratain MJ
J Clin Invest; 1998 Feb; 101(4):847-54. PubMed ID: 9466980
[TBL] [Abstract][Full Text] [Related]
14. Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11).
Chen S; Yueh MF; Bigo C; Barbier O; Wang K; Karin M; Nguyen N; Tukey RH
Proc Natl Acad Sci U S A; 2013 Nov; 110(47):19143-8. PubMed ID: 24191041
[TBL] [Abstract][Full Text] [Related]
15. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
Fakih MG; Ross ME; Starostik P
Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ
Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of irinotecan disposition and toxicity: a review.
Fujita K; Sparreboom A
Curr Clin Pharmacol; 2010 Aug; 5(3):209-17. PubMed ID: 20406168
[TBL] [Abstract][Full Text] [Related]
18. Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats.
Onoue M; Kurita A; Kado S; Matsumoto T; Kaneda N; Uchida K; Kato I; Yokokura T
Cancer Chemother Pharmacol; 2008 Apr; 61(4):595-605. PubMed ID: 17549477
[TBL] [Abstract][Full Text] [Related]
19. UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.
Gao J; Zhou J; Li Y; Lu M; Jia R; Shen L
Med Oncol; 2013; 30(3):604. PubMed ID: 23686699
[TBL] [Abstract][Full Text] [Related]
20. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
Iyer L; Das S; Janisch L; Wen M; Ramírez J; Karrison T; Fleming GF; Vokes EE; Schilsky RL; Ratain MJ
Pharmacogenomics J; 2002; 2(1):43-7. PubMed ID: 11990381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
